Eli Lilly and Company News - October 28, 2026

Eli Lilly Reports Retatrutide Beat Ozempic on Blood Sugar and Weight

Eli Lilly announced positive topline results from its TRANSCEND-T2D-2 Phase 3 trial of experimental drug retatrutide. In a head-to-head study of adults with...

Eli Lilly and Company Q3 2026 Earnings Preview: What Analysts Expect on October 29, 2026

Eli Lilly is expected to report Q3 2026 revenue of $22.58 billion and an EPS of $5.38, while the current stock price of $1,273.46 remains below the $1,343.50...